Clinical Trials Logo

Clinical Trial Summary

Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.


Clinical Trial Description

MydCombi is approved for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. The approved dose is 1 metered spray to the cornea of each eye to be dilated to be repeated after 5 minutes. This study will define the dilation of the pupil with ½ of the approved dose - a single metered spray to the cornea of each eye. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06217796
Study type Interventional
Source Eyenovia Inc.
Contact
Status Completed
Phase Phase 4
Start date November 28, 2023
Completion date January 9, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT02946125 - Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil Phase 2
Completed NCT05134974 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) Phase 3
Completed NCT04620213 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis Phase 3
Completed NCT03751631 - Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Phase 3
Completed NCT04907474 - Evaluation of Pupil Dilation Speed With the MAP Dispenser Phase 4
Completed NCT05880433 - The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations
Terminated NCT00690222 - Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery N/A
Recruiting NCT05829122 - Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty N/A
Completed NCT04396301 - Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco Phase 3
Completed NCT05223478 - Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Phase 3
Completed NCT03751098 - Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Phase 3
Completed NCT04024891 - Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Phase 2